FDA Panel Narrowly Approves Merck COVID-19 Pill

November 30, 2021 by Dan McCue
FDA Panel Narrowly Approves Merck COVID-19 Pill
This undated file image provided by Merck & Co. shows their new antiviral medication molnupiravir. An experimental COVID-19 drug that could soon become the first U.S.-authorized pill to treat the coronavirus faces one final hurdle Tuesday: A panel of government experts will scrutinize data on the medication from drugmaker Merck. (Merck & Co. via AP, File)

WASHINGTON — An advisory panel for the Food and Drug Administration narrowly approved the use of a COVID-19 pill manufactured by Merck.

If the agency accepts the recommendation, molnupiravir would be the first drug Americans could be prescribed and take at home to treat the virus.

The 13-10 vote by the panel came after an extended debate over the drug’s benefits and safety issues, such as the risk of birth defects if used during pregnancy.


In the end, the advisory panel said the drug should definitely not be used by pregnant women and should be labelled with extra safety precautions.


The panel backed the drug for adults with mild-to-moderate COVID-19 who face the greatest risks, including those with conditions like obesity, asthma and old age.


The pill is already authorized in the United Kingdom. Last week, Merck said final study results showed molnupiravir reduced hospitalization and death by 30% among adults infected with the coronavirus, when compared with adults taking a placebo. 

Dan can be reached at [email protected] and at https://twitter.com/DanMcCue

A+
a-

In The News

Health

Voting

Prescription Drugs

Pfizer Buying Spree Continues With $5.4B Hematology Deal

Pfizer will spend about $5.4 billion to buy Global Blood Therapeutics as the pharmaceutical giant continues to invest some of... Read More

Pfizer will spend about $5.4 billion to buy Global Blood Therapeutics as the pharmaceutical giant continues to invest some of the cash influx reaped during the COVID-19 pandemic. Pfizer said Monday that the acquisition will boost its capabilities in rare hematology. Global Therapeutics makes Oxybryta tablets... Read More

Over-the-Counter Birth Control? Drugmaker Seeks FDA Approval

WASHINGTON (AP) — For the first time, a pharmaceutical company has asked for permission to sell a birth control pill... Read More

WASHINGTON (AP) — For the first time, a pharmaceutical company has asked for permission to sell a birth control pill over the counter in the U.S. HRA Pharma’s application on Monday sets up a high-stakes decision for health regulators amid legal and political battles over women’s... Read More

July 8, 2022
by Natalie McCormick
Overturning Roe Has Birth Control and Emergency Contraceptives in High Demand

WASHINGTON — In the wake of the Supreme Court’s decision in Dobbs v. Jackson Women’s Health Organization, which overturned Roe... Read More

WASHINGTON — In the wake of the Supreme Court’s decision in Dobbs v. Jackson Women’s Health Organization, which overturned Roe v. Wade, demand for various forms of contraceptives, including the so-called morning-after pill, and long-lasting forms of birth control, has surged.  Doctors, women’s health clinics and... Read More

July 5, 2022
by Tom Ramstack
Drug Distributors Win Lawsuit Accusing Them of Opioid Abuse

CABELL COUNTY, W.Va. — A federal judge in West Virginia on Monday ruled in favor of drug distribution companies accused... Read More

CABELL COUNTY, W.Va. — A federal judge in West Virginia on Monday ruled in favor of drug distribution companies accused in a lawsuit of creating a public nuisance by distributing opioids that kill thousands of Americans each year. The judge said his ruling is "not based... Read More

April 27, 2022
by Tom Ramstack
Lawmakers Say Consulting Firm Marketing Contributed to Half-Million Opioid Deaths

WASHINGTON — A congressional panel cast suspicions on a global business consulting firm Wednesday as a potential villain in the... Read More

WASHINGTON — A congressional panel cast suspicions on a global business consulting firm Wednesday as a potential villain in the opioid epidemic that has killed more than a half-million Americans. A McKinsey & Co. official admitted to earning at least $86 million for helping pharmaceutical companies... Read More

April 19, 2022
by Dan McCue
Supreme Court Seeks Solicitor General Input on Biologic Drug Patents

WASHINGTON — The U.S. Supreme Court on Monday asked Solicitor General Elizabeth Prelogar to weigh in on a drug patent... Read More

WASHINGTON — The U.S. Supreme Court on Monday asked Solicitor General Elizabeth Prelogar to weigh in on a drug patent case the outcome of which could ultimately be worth billions of dollars. The case, Amgen v. Sanofi, emanates from the U.S. District Court for the Federal... Read More

News From The Well
scroll top